Добірка наукової літератури з теми "Coates and Company"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Coates and Company".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Coates and Company"
1
Englund, Magnus. "Isokon Furniture — Modernist Dreams in Plywood." Louis I. Kahn – The Permanence, no. 58 (2018): 82–85. http://dx.doi.org/10.52200/58.a.ky5uaj0p.
Повний текст джерелаАнотація:
The Isokon Furniture Company was never commercially successful, yet its legacy has stubbornly refused to die and disappear. Even today, this radical collection of plywood furniture is manufactured and used. The main reason is of course the names associated with it: Jack Pritchard, Wells Coates, Marcel Breuer, Walter Gropius, László Moholy-Nagy and – more recently – Edward Barber & Jay Osgerby. The genius little Isokon Penguin Donkey, first designed by the Austrian émigré architect Egon Riss in 1939 and marketed by publisher Allen Lane’s then new imprint Penguin Books, is particularly popular with younger generations of design students.
2
Coates, L. C., A. Kronbergs, A. T. Sprabery, S. Y. Park, B. Combe, and A. Deodhar. "SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1157–58. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3994.
Повний текст джерелаАнотація:
Background:Biologic disease-modifying antirheumatic drugs such as ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, are commonly prescribed to patients with psoriatic arthritis (PsA) in combination with conventional synthetic disease-modifying antirheumatic drugs (cDMARDs). Previous studies have shown that, after 24 weeks of treatment, IXE is efficacious with or without concomitant cDMARD therapy in patients with active PsA.1,2However, there is limited evidence demonstrating efficacy and safety after 3 years of treatment.Objectives:To evaluate the long-term (3-year) efficacy and safety of IXE in patients with active PsA from SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) based on concomitant cDMARD use.Methods:Patients were subdivided into the following subgroups: 1) no cDMARD use for 3 years (ixekizumab monotherapy); 2) methotrexate (MTX) use without interruption (i.e., ≤14-day gap of not using MTX), but allowing a change of MTX dose; and 3) any cDMARD (MTX, sulfasalazine, leflunomide, ciclosporin, hydroxychloroquine) use during 3 years without interruption (i.e., ≤14-day gap of not using cDMARDs), but allowing a switch of cDMARD type and/or change of dose. The post-hoc integrated analysis assessed efficacy and safety up to 3 years by three subgroups. Efficacy outcomes included the American College of Rheumatology (ACR) 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100, Health Assessment Questionnaire-Disability Index (HAQ-DI) ≥0.35-point improvement. Missing data were imputed using modified non-responder imputation. The IXE 80 mg every 4 weeks (IXEQ4W) dose data are reported here.Results:Overall, IXE-treated patients showed improvement in all efficacy outcomes over 156 weeks, regardless of concomitant cDMARD use. ACR response rates by concomitant cDMARD use at 156 weeks are highlighted in Figure 1. Patients treated with IXEQ4W in the no cDMARD use, MTX, and any cDMARD use subgroups had similar ACR20 (59.1%, 67.0%, and 66.1%, respectively), ACR50 (46.2%, 47.4%, and 46.8%, respectively), and ACR70 (30.7%, 28.4%, and 28.1%, respectively) response rates at 156 weeks. Patients treated with IXEQ4W in the three subgroups also had similar PASI75 (65.5%, 60.8%, and 59.8%, respectively), PASI90 (53.6%, 49.7%, and 48.0%, respectively), and PASI100 (42.2%, 46.2%, and 42.4%, respectively) response rates at 156 weeks. The proportion of patients achieving HAQ-DI improvement ≥0.35 in the three subgroups (51.9%, 45.0%, and 47.5%, respectively) was comparable. The safety profile of IXEQ4W was consistent with that previously reported.1,2A similar proportion of IXEQ4W-treated patients in the three subgroups reported ≥1 treatment-emergent adverse events (TEAEs) regardless of the addition of MTX or other cDMARDs (91.0%, 84.1%, and 83.2%, respectively), and the majority of TEAEs were mild or moderate in all three subgroups.Conclusion:IXEQ4W provided sustained improvements in the signs and symptoms of active PsA. While there are some numerical differences in ACR20/50/70 as well as PASI75/90/100, the overall responses with or without the addition of MTX or other cDMARDs were similar. In this post-hoc analysis, it appears that, for sustained responses over time, IXEQ4W does not require the addition of MTX or other cDMARDs. Addition of MTX or other cDMARDs to IXEQ4W did not negatively impact its favorable long-term safety profile.References:[1]Coates LC, Kishimoto M, Gottlieb A, et al. RMD Open 2017.[2]Nash P, Behrens F, Orbai A-M, et al. RMD Open 2018.Disclosure of Interests:Laura C Coates: None declared, Andris Kronbergs Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, So Young Park Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Bernard Combe Grant/research support from: Novartis, Pfizer, Roche-Chugai, Consultant of: AbbVie; Gilead Sciences, Inc.; Janssen; Eli Lilly and Company; Pfizer; Roche-Chugai; Sanofi, Speakers bureau: Bristol-Myers Squibb; Gilead Sciences, Inc.; Eli Lilly and Company; Merck Sharp & Dohme; Pfizer; Roche-Chugai; UCB, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB
3
Smolen, J. S., A. Sebba, E. Ruderman, A. Gellett, C. Sapin, A. T. Sprabery, S. Liu Leage, S. Pillai, P. Reis, and P. Nash. "OP0228 EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB (SPIRIT-H2H) WITH AND WITHOUT CONCOMITANT CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 143–44. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4615.
Повний текст джерелаАнотація:
Background:Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100) (primary endpoint) in patients (pts) with active PsA from SPIRIT-H2H1. SPIRIT-H2H had two major secondary endpoints and achieved both: noninferiority of IXE to ADA for ACR50 at Wk 24, and superiority of IXE to ADA for PASI 100 at Wk 24.Objectives:To determine how concomitant conventional synthetic DMARD (csDMARD) use affects safety and efficacy of IXE and ADA in prespecified subgroups defined by biologic monotherapy, concomitant MTX use, and concomitant csDMARD use through Wk 52 in SPIRIT-H2H.Methods:SPIRIT-H2H (NCT03151551) was a 52-week, multicentre, randomised, open-label, assessor-blinded, parallel-group study evaluating the efficacy and safety of IXE versus ADA in adults with PsA and naïve to biologic DMARDs. Patients were required to have active PsA fulfilling Classification for Psoriatic Arthritis (CASPAR) criteria and ≥3/68 tender and ≥3/66 swollen joints, ≥3% plaque psoriasis BSA involvement, no prior treatment with bDMARDs, and with prior inadequate response to ≥1 csDMARD (but not necessarily current treatment with csDMARDs). Randomization (1:1) was stratified by concomitant use of csDMARD and the presence/absence of moderate to severe PsO (baseline: BSA≥10% + PASI≥12, + static Physician’s Global Assessment≥3). Patients (N=566) received IXE/ADA through 52 wks according to the labelled dose dependent on presence/absence of moderate-to-severe PsO. In this prespecified subgroup analysis by presence or absence of csDMARDs, efficacy outcomes through wk 52 were compared between IXE and ADA using logistic regression models and Fisher’s exact tests. Missing data were imputed using non-responder imputation.Results:At baseline, 167 of 283 IXE-treated patients and 169 of 283 ADA-treated patients had concomitant MTX use. Of these, 9.0% (15/167) and 7.1% (12/169) treated with IXE and ADA, respectively, were taking an additional csDMARD (sulfasalazine, cyclosporine, or leflunomide). A significantly greater proportion of patients on IXE versus ADA achieved the primary endpoint or PASI 100 when used as monotherapy or in combination with csDMARD (Figure 1A and 1C). At Wk 52, the proportion of patients achieving ACR50 was not statistically different between IXE and ADA, regardless of monotherapy or concomitant csDMARD use (Figure 1B). A significantly higher proportion of patients achieved MDA on IXE compared to ADA in the monotherapy subgroup (49% vs 33%), while the response rates were similar in both combination subgroups (Figure 1D). These data support consistent ACR50, PASI 100, and MDA response for IXE across all three subgroups. Frequencies of adverse events were similar across the three subgroups for IXE and ADA (Figure 2).Conclusion:As with prior studies,2,3consistent efficacy across multiple PsA disease-specific endpoints was observed with IXE in SPIRIT-H2H, regardless of whether IXE was taken as monotherapy or in combination with MTX or another csDMARD. No unexpected safety signals were found for either agent.References:[1]Mease et al, Ann Rheum Dis 2020;79:123-31.[2]Coates et al, RMD Open 2017;3:e000567.[3]Nash et al, RMD Open 2018;4:e000692.Disclosure of Interests:Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Anthony Sebba Consultant of: Genentech, Gilead, Lilly, Regeneron Pharmaceuticals Inc., Sanofi, Speakers bureau: Lilly, Roche, Sanofi, Eric Ruderman Consultant of: Pfizer, Amanda Gellett Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Sreekumar Pillai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Paulo Reis Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB
4
Coates, L. C., D. Sandoval, R. Bolce, C. Y. Lin, K. Stenger, A. T. Sprabery, and A. Kavanaugh. "AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1301–2. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1514.
Повний текст джерелаАнотація:
Background:Ixekizumab (IXE), a high-affinity monoclonal antibody targeting IL-17A, has demonstrated superiority in achieving the combined endpoint of ACR50 and PASI100 at week (Wk) 24 compared to adalimumab (ADA) in the SPIRIT-H2H trial [1]. In this analysis, we looked at the efficacy responses at the individual patient (pt) level to assess consistency over time and at each visit.Objectives:To determine the American College of Rheumatology 50% (ACR50) response and Disease Activity in psoriatic arthritis (PsA) (DAPSA) response in pts treated with IXE and describe response consistency over time and at each visit from Wk 24 through Wk 52.Methods:This post-hoc analysis used data from SPIRIT-H2H (NCT03151551), a phase3b/4 randomised, open-label parallel-group study between IXE and ADA. Pts were randomised to receive either IXE 80 mg, every 4 Wks (IXE Q4W)) or ADA 40 mg, every 2 Wks (ADA Q2W)). The proportion (%) of pts in the intent-to-treat population who achieved each endpoint, either ACR50 or DAPSA≤14, at Wk 24 and at each post-baseline visit out to Wk 52 was assessed. Nine pts with active psoriasis and body surface area (BSA) ≥3% were assessed as PASI=0 at baseline, a medical inconsistency that was resolved using medical judgement. These pts were considered PASI100 responders if PASI=0 and BSA=0 at post baseline visits.Results:A total of 566 patients enrolled in the trial received either IXE (N=283) or ADA (N=283). Of the 143 pts treated with IXE who achieved ACR50 at Wk 24, 65% (N=93) maintained ACR50 at every visit. In total, 83% (N=118) of the ACR50 achievers at Wk 24 maintained ACR50 with some (18% (N=25)) fluctuations, between ACR50 and ACR20 (Figure 1). Of the 132 pts treated with ADA who achieved ACR50 at Wk 24, 55% (N=72) maintained ACR50 at every visit. In total, 80% (N=105) of ACR50 achievers maintained ACR50 with some (25% (N=33)) fluctuations between ACR50 and ACR20 (Table 1). Furthermore, of the174 pts treated with IXE who achieved low DA (DAPSA≤14) at Wk 24, 68% (N=119) maintained low DA at every visit. Of the low DA achievers at Wk 24, 82% (N=142) of pts maintained low DA with some (13% (N=23)) fluctuations between moderate and low DA (Figure 1B). Of the 171 pts treated with ADA who achieved low DA at Wk 24; 57% (N=97) maintained low DA at every visit. In total, 77% (N=131) of low DA achievers at Wk 24 maintained low DA with some (20% (N=34)) fluctuations between moderate and low DA (Table 1).Conclusion:This analysis demonstrates that a numerically higher proportion of pts treated with IXE versus ADA show consistency of response, as measured by ACR50 and DAPSA responses, over time and for each visit at the pt level.References:[1]Mease et al. Ann Rheum Dis. 2020;79(1):123-131Table 1.Consistency over time of the effect of ADA in pts with PsA.IXE Q4W(N=283)ADA Q2W(N=283)ACR50Response,% (n)DAPSA≤14low DA,% (n)ACR50Response,% (n)DAPSA≤14low DA,% (n)Patients who achieved the response at Wk 2451% (143)61% (174)47% (132)60% (171)Achieved endpoint at Wk 24 and maintained out to Wk 52 with some fluctuations*83% (N=118)82% (N=142)80% (105)77% (131)Maintained endpoint at every visit65% (N=93)68% (N=119)55% (72)57% (97)Had some fluctuations*18% (N=25)13% (N=23)25% (33)20% (34)* fluctuations between ACR50 and ACR20, or between low and moderate disease activity.Figure 1.Heatmap diagram describing consistency over time of the effect of IXE in pts with PsA who achieved DAPSA≤14 (low disease activity) at Wk 24.Acknowledgements :Edel Hughes, an employee of Eli Lilly and Company, provided editorial and writing support.Disclosure of Interests:Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB., Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, David Sandoval Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Rebecca Bolce Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Chen-Yen Lin Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Keri Stenger Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company; Johnson and Johnson, Employee of: Eli Lilly and Company, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Eli Lilly, BMS, Pfizer, Novartis, Janssen.
5
Coates, L. C., M. Nissen, C. El Baou, J. Zochling, A. Marchesoni, S. Liu Leage, E. Soriano, V. F. Azevedo, K. Machold, and C. Sapin. "FRI0332 EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM THE SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÏVE TO BDMARDS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 758.1–758. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2830.
Повний текст джерелаАнотація:
Background:Psoriatic arthritis (PsA) is a chronic systemic disease with manifestations affecting musculoskeletal and extra-articular domains. Treatment and assessment of response are therefore major challenges in routine clinical practice. Minimal disease activity (MDA) is a multidimensional endpoint that can define a treatment target1. In SPIRIT-H2H2, a head-to-head clinical trial comparing the efficacy and safety of ixekizumab (IXE) versus) to adalimumab (ADA), the percentage of patients simultaneously achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100), was the primary endpoint in order to reflect improvement in two domains of PsA.Objectives:To evaluate how individual components of the simultaneous achievement of ACR50 and PASI100 compare with those of MDA at week 24.Methods:Patients with active PsA (defined as those with a tender joint count [TJC] ≥ 3/68, a swollen joint count [SJC] ≥ 3/66 and a body surface area [BSA] of active plaque psoriasis ≥ 3%) were randomised 1:1 to approved dosing (according to baseline psoriasis involvement) of IXE or ADA in SPIRIT-H2H, an open label, assessor-blinded study.The proportion of patients meeting each criterion of the composite endpoints was calculated for the intent-to-treat ([ITT], N=566) population and the population of MDA responders at Week 24 (N=235). Missing individual responses were imputed with non-responder status. Spidergrams were generated using SAS 9.4.Results:For both the overall ITT population and the MDA responders population, the use of PASI≤1 or BSA≤3% in the skin-related component of the MDA contributed to the higher response rate relative to the PASI100 response. Thus, the PASI100 response is a more stringent endpoint. Proportions of responders are similar across MDA and ACR50+PASI100 individual components for HAQ and SJC. The high baseline TJC levels (mean TJC: IXE=19.1, ADA=21.3) as opposed to lower levels observed for baseline SJC (mean SJC: IXE=10.1, ADA=10.7) made MDA-TJC criterion (≤1) more difficult to achieve than the equivalent criterion of the ACR50+PASI100 endpoint.Conclusion:Despite the differences in criteria definitions, there are consistent response patterns in the individual components of the simultaneous ACR50+PASI100 and MDA endpoints in particular for the peripheral arthritis domain.References:[1]Smolen, Josef S et al. “Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.”Annals of the rheumatic diseasesvol. 77,1 (2018): 3-17.[2]Mease PJ The SPIRIT H2H study group, et al. “A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.”Annals of the Rheumatic Diseases2020;79:123-131.Disclosure of Interests:Laura C Coates: None declared, Michael Nissen Grant/research support from: Abbvie, Consultant of: Novartis, Lilly, Abbvie, Celgene and Pfizer, Speakers bureau: Novartis, Lilly, Abbvie, Celgene and Pfizer, Celine El Baou Consultant of: Eli Lilly and Company, Jane Zochling Employee of: Jannssen Cilag, Speakers bureau: Janssen Cilag, AbbVie, Novartis, UCB, BMS, Eli Lilly, Antonio Marchesoni Speakers bureau: Abbvie, Pfizer, UCB, Novartis, Celgene, Eli Lilly, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Enrique Soriano Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Speakers bureau: AbbVie, Amber, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc, Roche, Valderilio F Azevedo Grant/research support from: Abbvie, Janssen, Bristol-Myers Squibb, Boehringer-Ingelheim, Lilly and Novartis, Consultant of: Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Speakers bureau: Sandoz, Celltrion, Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Klaus Machold Grant/research support from: AbbVie, MSD, UCB, Consultant of: Arsanis, Astro, Baxter, BMS, Celgene, Eli-Lilly, MSD, Pfizer, Roche, Novartis, Sandoz, Speakers bureau: MSD, Pfizer, BMS, Janssen-Cilag, Sandoz, Novartis, Eli-Lilly, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company
6
Van Hal, T., M. Mulder, M. Wenink, M. Pasch, J. Van den Reek, and E. De Jong. "AB0842 DISCOVERY OF ARTHRITIS IN PSORIASIS FOR EARLY RHEUMATOLOGIC REFERRAL (DAPPER): A CROSS-SECTIONAL STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1727.1–1727. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4745.
Повний текст джерелаАнотація:
Background:One in three patients with psoriasis (Pso) will develop psoriatic arthritis (PsA) (1). When untreated, this can lead to disability and irreversible joint damage (2). Current screening methods are mostly based on questionnaires. These lack specificity and sensitivity (3,4). Thus, a significant portion of PsA patients remains undetected.Objectives:Our main objective is to ascertain the prevalence of PsA in a cohort of Pso patient, treated at a dermatology outpatient clinic. Secondary, we wish to make a referral tool for dermatologist to detect patients suspected of PsA.Methods:A sample of 300 patients, stratified for current skin therapy (topical, systemic non-biologic, biologic), will be screened by a rheumatology resident for PsA signs and symptoms. When PsA is suspected, patients are referred to a rheumatologist for confirmation. We gather information about demography, treatment (past and current) and comorbidity. On top of that, we gather data on disease specifics (age of onset, disease duration, severity). We store biomaterials and DNA. Eventually, all these data will be used to form a more specific prediction model which can be used at the dermatology department for more efficient referral.Results:We will present preliminary data of the first 100 patients. In this cohort, we found 14 patients with known PsA. 10 patients were suspected of (previously undiagnosed) PsA, and were referred to a rheumatology clinic. Three cases were confirmed, and 4 are still under analysis. This makes the prevalence of PsA in Pso 17-21%. Of these three new cases, one was treated with topical therapy only, one was treated with a biologic, and one received targeted therapy. In the patients with PsA, we found a higher amount of men. On top of that, we found a trend towards more intensive therapy. This may be due to indication bias, were the presence of arthritis may lead to a more aggressive treatment. Interestingly, 2 of the 3 previously undiagnosed PsA patients were treated with a biological for their skin symptoms.Conclusion:Preliminary data of the DAPPER study reveal that the prevalence of confirmed PsA in Pso patients is 17%. If all suspected PsA are confirmed, this rises to 21%. Even under systemic biologic treatment, arthritis can still be active.References:[1]Mease PJ, Gladman DD, Papp KA et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69(5):729-735.[2]Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42(12):1460-1468.[3]Coates LC, Aslam T, Al BF et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013;168(4):802-807.[4]Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72(5):736-740.Disclosure of Interests:Tamara van Hal Speakers bureau: Lilly Eli, Michelle Mulder: None declared, Mark Wenink: None declared, Marcel Pasch: None declared, Juul Van den Reek Speakers bureau: Abbvie, Eli Lilly, Elke De Jong Grant/research support from: Abbvie, Janssen Pharmaceutica, Consultant of: AbbVie, Janssen Pharmaceutica, Novartis, Eli Lily and Company, Celgene, and Leo Pharma., Speakers bureau: AbbVie, Janssen Pharmaceutica, Novartis, Eli Lily and Company, Celgene, and Leo Pharma.
7
Poddubnyy, D., P. J. Mease, F. Van den Bosch, J. Braun, A. Gottlieb, L. C. Coates, V. Chandran, et al. "AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1715.1–1716. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2719.
Повний текст джерелаАнотація:
Background:Inflammatory involvement of the axial skeleton (sacroiliac joints and / or spine) is one of the relatively frequent musculoskeletal manifestations associated with psoriasis / psoriatic arthritis (PsA). There is an urgent need for an evidence-based definition for axial involvement in PsA that would identify a subgroup of patients within the heterogeneous PsA population to conduct observational, interventional and translational studies. ASAS and GRAPPA embarked on a collaborative initiative to develop a definition of axial involvement in PsA.Objectives:To perform a survey to identify variables relevant in the identification of the presence of axial involvement in PsA among members of ASAS and GRAPPA.Methods:The online survey utilized thePAPRIKAmethodology (PotentiallyAllPairwiseRanKings of all possibleAlternatives) that determines decision-makers’ part-worth utilities representing the relative importance of the attributes. Participants were exposed to number of clinical scenarios and were prompted to decide which of the scenarios is more compatible with axial involvement in PsA unless they are equal (Figure). The constant stem of each scenario was “a patient diagnosed with psoriatic arthritis fulfilling the CASPAR criteria”; the variable part included 13 common spondyloarthritis variables (Table). Variables were ranked according to their relative importance.Results:The survey was completed by 186 ASAS/GRAPPA members (63 ASAS only, 80 GRAPPA only, and 43 both societies). The ranking of the variables is presented inTable. The highest ranked parameters indicative of axial involvement in a patient with PsA were presence of typical radiographic or MRI changes in the sacroiliac joints and/or spine followed by the presence of chronic back pain and then inflammatory back pain. A separate analysis of ASAS and GRAPPA members provided the similar results concerning the relevance of the variables.Conclusion:Objective signs of inflammatory involvement of the axial skeleton are the most important indicators of axial disease in PsA in the opinion of the experts. A prospective cohort study is currently being planned to address the value of these and other variables in defining axial involvement in PsA.Table.Ranking of the parameters relevant to deciding on the presence of axial involvement in a PsA patient in the opinion of ASAS and GRAPPA members (n=186).NParametersMedian rankMean rank1Presence of structural damage on an X-ray of SIJ22.82Presence of structural damage on an X-ray of spine3.54.13Presence of subchondral BME / osteitis on MRI of SIJ compatible with SpA44.54Presence of BME / osteitis on MRI of spine compatible with SpA455History or current presence of back pain5.55.86History of or current presence of inflammatory back pain5.567Good response of back pain to non-steroidal anti-inflammatory drugs87.88HLA-B2788.19Family history for SpA9.5910Elevated C-reactive protein109.311Presence of peripheral arthritis and/or enthesitis and/or dactylitis109.412Presence of anterior uveitis109.513Presence of inflammatory bowel disease109.6BME=bone marrow edema, MRI=magnetic resonance imaging, SIJ=sacroiliac joints, SpA=spondyloarthritisDisclosure of Interests:Denis Poddubnyy Grant/research support from: AbbVie, MSD, Novartis, and Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Filip van den Bosch Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Juergen Braun Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Eli Lilly and Company, Medac, MSD (Schering Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi- Aventis, and UCB Pharma, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Alice Gottlieb Grant/research support from: Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, Consultant of: AbbVie, Allergan, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, BMS, Celgene, Dermira, Incyte, Eli Lilly, Janssen, LEO Pharma, Novartis, Reddy Labs, Sun Pharmaceutical Industries, UCB, Valeant, Xbiotech, Laura C Coates: None declared, Vinod Chandran Grant/research support from: Abbvie, Celgene, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lily, Janssen, Novartis, Pfizer, UCB, Employee of: Spouse employed by Eli Lily, Philip Helliwell: None declared, Deepak Jadon: None declared, Joachim Sieper Consultant of: AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, and UCB Pharma, Speakers bureau: AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, and UCB Pharma, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead Sciences, Inc., Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director of Imaging Rheumatology BV, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant
8
Gottlieb, A. B., F. Behrens, P. Nash, J. F. Merola, K. Ding, P. Pellet, L. Pricop, and I. Mcinnes. "FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 763.2–764. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4736.
Повний текст джерелаАнотація:
Background:Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis.1Secukinumab (SEC), an IL-17A inhibitor, provided significantly greater PASI 75/100 responses in a head-to-head trialversus (vs.) etanercept, a TNF inhibitor, in patients (pts) with moderate-to-severe plaque psoriasis.2The objective of the EXCEED study (NCT02745080) was to investigate whether SEC is superior to adalimumab (ADA), a TNF inhibitor, as monotherapy in biologic-naive active PsA pts with active plaque psoriasis (defined as having at least one psoriatic plaque of ≥2 cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis).Objectives:To report the pre-specified skin outcomes from the EXCEED study in the subset of pts with at least 3% body surface area (BSA) affected with psoriasis at baseline.Methods:Head-to-head, phase-3b, randomised, double-blind, active-controlled, multicentre, parallel-group trial: pts were randomised to receive SEC 300 mg subcutaneous at baseline, Week 1-4, followed by dosing every 4 weeks (q4w) until Week 48 or ADA 40 mg subcutaneous at baseline followed by same dosing q2w until Week 50. The primary endpoint was superiority of SECvs.ADA on ACR20 response at Week 52. Pre-specified outcomes included the proportion of pts achieving a combined ACR50 and PASI 100 response, PASI 100 response, and absolute PASI score ≤3. Missing data was handled using multiple imputation.Results:853 pts were randomised to receive SEC (n=426) or ADA (n=427). At baseline, there were 215 and 202 pts having at least 3% BSA affected with psoriasis in the SEC and ADA groups, respectively. A higher proportion of patients achieved simultaneous improvement in ACR50 and PASI 100 response with SECvs.ADA (30·7%vs.19·2%; P=0·0087 [Figure]). Higher efficacy was demonstrated for SECvs.ADA for PASI 100 responses and for the proportion of pts achieving absolute PASI score ≤3 (Table).Conclusion:In this pre-specified analysis, SEC provided higher responses compared to ADA in achievement of simultaneous improvement of joint and skin disease (combined ACR50 and PASI 100 response) and in skin specific endpoints (PASI 100 and PASI score ≤3) at Week 52.References:[1]Coates LC and Helliwell PS.Clinical Med.2017;17:65–70.[2]Langley RG et al.N Engl J Med.2014;371:326–38.Figure.Combined ACR50 and PASI 100 Response through Week 52Table.Skin Specific Outcomes at Week 52Endpoints, data is presented as % responseSEC 300 mg(N = 215)ADA 40 mg(N = 202)P-value (unadjusted)PASI 10046·029·70·0007Absolute PASI score ≤379·265·00·0015P value vs. adalimumab; Unadjusted P values are presentedN, number of patients in psoriasis subsetMultiple imputation was used for handling missing dataADA, adalimumab; BSA, body surface area; PASI, psoriasis area severity index; SEC, secukinumabAcknowledgments:Suchita Dubey (Novartis) provided medical writing support.Disclosure of Interests:Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Joseph F. Merola Consultant of: Merck, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB Pharma, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and LEO Pharma, Kevin Ding Employee of: Novartis, Pascale Pellet Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB
9
Lal, Ashutosh, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, and Sujit Sheth. "Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease." Blood 138, Supplement 1 (November 5, 2021): 4162. http://dx.doi.org/10.1182/blood-2021-145752.
Повний текст джерелаАнотація:
Abstract Background Sickle cell disease (SCD) and thalassemia are inherited hemoglobinopathies characterized by lifelong anemia. In SCD, a single mutation in the β-globin gene results in sickle hemoglobin (HbS) that polymerizes upon deoxygenation, causing red blood cells (RBCs) to sickle leading to a variety of complications. In thalassemia, mutation(s) in α- or β-globin genes result in reduced or absent adult Hb causing ineffective erythropoiesis and downstream complications. The resultant anemias are exacerbated by impaired RBC function due to decreased ATP content. Supportive care and agents like hydroxyurea are used most in SCD, with a subset of patients (pts) on regular transfusions. Regular or episodic transfusions, with their own set of complications, are the mainstay of treatment for thalassemias. Etavopivat, a potent, selective, oral, small molecule activator of erythrocyte pyruvate kinase (PKR) increases ATP and decreases 2,3 diphosphoglycerate (2,3-DPG). In a Phase 1 study, etavopivat 300‒600 mg once daily in pts with SCD not regularly transfused was well-tolerated, improved hematological markers, decreased hemolysis, and improved markers of RBC functional health (Brown et al. EHA 2021 # EP1202). Etavopivat 200 and 400 mg once daily (dose levels predicted to provide the desired pharmacodynamic response profiles) is being evaluated in a Phase 2/3 study of pts with SCD who are not on chronic transfusions (The Hibiscus Study, NCT04624659). Herein we describe the design of a Phase 2, open-label, multicenter study (NCT04987489) evaluating the efficacy and safety of etavopivat in pts with: SCD on chronic transfusions (Cohort A), transfusion-dependent thalassemia (Cohort B), and non-transfusion-dependent thalassemia (Cohort C). Study Design and Methods Up to 20 pts aged 12-65 years will be enrolled in each of the three cohorts described above. Pts will receive etavopivat 400 mg once daily for 48-wks (Figure). In cohorts A and B, pts must have received ≥6 RBC units in the 24 wks before the first dose of etavopivat without a >35-day transfusion-free period during that period and be on iron chelation therapy for >3 months before enrollment. Additionally, pts in Cohort A should have received ≥24 monthly transfusions for the prevention or treatment of primary stroke. Pts in Cohort C should have a Hb ≤10 g/dL. Key exclusion criteria include significant infection, hepatic/renal dysfunction, history of malignancy/cardiac/pulmonary disease, a drug malabsorption disorder, prior/concomitant therapies ≤3 months before the first dose (eg, chronic systemic glucocorticoids, new chelation therapy). Baseline assessments will include medical, disease, transfusion, and medication histories. Transfusions received during the study (every ~3-5 wks) will be recorded and include Hb values before and ≥15 minutes after transfusion, number of RBC units, and volume of packed RBCs. If a pt has an increase in pre-transfusion Hb of ≥1.0 g/dL compared with their baseline pre-transfusion Hb, the Investigator may delay transfusion by 1 wk or reduce the number of RBC units transfused. In pts with SCD, RBC exchange may also be performed. The primary endpoint for Cohorts A/B is erythroid response defined as the proportion of pts with ≥20% reduction in transfusions over a continuous 12-wk treatment period versus baseline, and for Cohort C is Hb response at Wk 12 defined as an increase in Hb of ≥1.0 g/dL from baseline. For Cohorts A/B, secondary and exploratory endpoints include the proportion of pts with a reduction in transfusions over 12 wks of ≥33% and ≥50%, respectively, and a reduction in transfusions over 12, 24, and 48 wks; and for Cohort C, Hb response at Wks 24 and 48, and changes from baseline in Hb over 12, 24, and 48 wks. The following additional endpoints will be assessed for all cohorts: changes from baseline in quality of life as assessed via the Short Form Health Survey and Patient-Reported Outcome Measurement Information System Fatigue Scale; changes from baseline in the levels of serum ferritin at 12, 24, and 48 wks; liver iron at 48 wks; 2,3-DPG and ATP; pharmacokinetics; and safety. All primary endpoints will be analyzed using a 1-sided test at α=0.025. Summary Etavopivat is a novel, investigational, PKR activator designed to improve the functional health of RBCs. This Phase 2 study will assess the safety of etavopivat and its impact on Hb levels and transfusion burden in pts with SCD or thalassemia. Figure 1 Figure 1. Disclosures Lal: Chiesi: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; bluebird bio, Inc.: Research Funding; Protagonist Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios Pharmaceuticals: Consultancy; Insight Magnetics: Research Funding; Novartis: Research Funding; Terumo Corporations: Research Funding; La Jolla Pharmaceutical Company: Research Funding. Brown: Novo Nordisk: Consultancy; Novartis: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Pfizer: Research Funding; Global Blood Therapeutics: Consultancy, Research Funding. Coates: Apo Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Chiesi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Research Funding; Forma Pharma: Consultancy; Sangamo: Consultancy; UpToDate: Patents & Royalties; Vifor Pharma: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kalfa: Agios Pharmaceuticals, Inc.: Other: Steering Committee, Research Funding; FORMA Therapeutics, Inc: Research Funding. Kwiatkowski: Bioverativ: Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Agios Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; CRISPR: Research Funding; Imara: Consultancy, Research Funding; Silence Therapeutics: Consultancy; Sangamo: Research Funding; bluebird bio: Consultancy, Research Funding; Chiesi: Research Funding; Vertex: Research Funding. Brevard: Forma Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Potter: Forma Therapeutics, Inc: Current Employment, Current equity holder in publicly-traded company; Bristol Myers Squibb: Ended employment in the past 24 months. Wood: Forma Therapeutics, Inc: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. Sheth: Bluebird bio: Consultancy; CRISPR: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Imara: Research Funding; Chiesi: Consultancy; Agios: Consultancy; Dispersol: Research Funding.
10
Ovseiko, P. V., L. Gossec, L. Andreoli, U. Kiltz, L. Van Mens, N. Hassan, M. Van der Leeden, et al. "THU0580 EULAR TASK FORCE ON GENDER EQUITY IN ACADEMIC RHEUMATOLOGY: PRELIMINARY SURVEY FINDINGS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 531.2–532. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3384.
Повний текст джерелаАнотація:
Background:Women represent an increasing proportion of the overall rheumatology workforce, but are underrepresented in academic rheumatology, especially in leadership roles [1].Objectives:The EULAR Task Force on Gender Equity in Academic Rheumatology has been convened to establish the extent of the unmet need for support of female rheumatologists, health professionals and non-clinical scientists in academic rheumatology and develop a framework to address this through EULAR and EMEUNET.Methods:To investigate gender equity in academic rheumatology, an anonymous web-based survey was targeted at the membership of EULAR and Emerging EULAR Network (EMEUNET) and their wider networks. The survey was developed based on a narrative literature review [1], best practice from The Association of Women in Rheumatology, a survey of task force members and face-to-face task force discussions. Personal experiences were explored and 24 potential interventions to aid career advancement were ranked. Statistics were descriptive with significance testing for male/female responses compared using chi-squared/t-tests. The level of significance was set at p<0.001.Results:A total of 301 respondents from 24 countries fully completed the survey. By profession, 290 (86.4%) were rheumatologists, 19 (6.3%) health professionals, and 22 (7.3%) non-clinical scientists. By gender, 217 (72.1%) were women, 83 (27.6%) men, and 1 (0.3%) third gender. By age, 203 (67.5%) were 40 or under. By ethnicity, 30 (10.0%) identified themselves as ethnic minority. A high proportion of respondents reported having experienced gender discrimination (47.2% total: 58.1% for women and 18.1% for men) and sexual harassment (26.2%: 31.8% and 10.8% respectively) (Figure 1). Chi-squared tests on the numbers on which these proportions were based showed statistically significant differences between women and men in having experienced gender discrimination (Χ2=36.959 (df=1), p <0.001) and sexual harassment (Χ2=12.633 (df=1), p <0.001). The highest-ranked interventions for career advancement regardless of respondents’ gender included: leadership skills training; speaking/presentation/communication skills training; information on training/career pathways; effective career planning training; support on grant writing applications; and high-impact scientific writing master-classes (Figure 2). Only 8 of 24 proposed interventions showed a significantly higher ranking (p<0.001) by female respondents and these typically related to promotion of female role models and gender-balance in committees, editorial boards and research funding (Figure 2).Figure 1.Perceived gender discrimination and sexual harassment, 301 responsesFigure 2.Mean perceived utility of potential interventions for career advancement by gender and statistically significant gender differences (p<.001), 300 responsesConclusion:The results of the survey will inform the development of task force policy proposals for interventions to support career advancement among EULAR and EMEUNET members. The identified interventions have potential to support career advancement of all rheumatologists, health professionals and non-clinical scientists regardless of gender.References:[1]Andreoli L, Ovseiko PV, Hassan N, Kiltz U, van Mens L, Gossec L, et al. Gender equity in clinical practice, research and training: Where do we stand in rheumatology? Joint, Bone, Spine: Revue du Rhumatisme. 2019;86(6):669-672.Acknowledgments:We gratefully acknowledge the rheumatologists, health professionals and non-clinical scientists who responded to the survey.Disclosure of Interests:Pavel V Ovseiko: None declared, Laure Gossec Grant/research support from: Lilly, Mylan, Pfizer, Sandoz, Consultant of: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis, UCB, Laura Andreoli: None declared, Uta Kiltz Grant/research support from: AbbVie, Amgen, Biogen, Novartis, Pfizer, Consultant of: AbbVie, Biocad, Eli Lilly and Company, Grünenthal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB, Leonieke van Mens: None declared, Neelam Hassan: None declared, Marike van der Leeden: None declared, Heidi J Siddle: None declared, Alessia Alunno: None declared, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Nemanja Damjanov Grant/research support from: from AbbVie, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Florence Apparailly: None declared, Caroline Ospelt Consultant of: Consultancy fees from Gilead Sciences., Irene van der Horst-Bruinsma Grant/research support from: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Consultant of: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Elena Nikiphorou: None declared, Katie Druce Speakers bureau: Pfizer and Lilly, Zoltán Szekanecz Grant/research support from: Pfizer, UCB, Consultant of: Sanofi, MSD, Abbvie, Pfizer, Roche, Novertis, Lilly, Gedeon Richter, Amgen, Alexandre Sepriano: None declared, Tadej Avcin: None declared, George Bertsias Grant/research support from: GSK, Consultant of: Novartis, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Anne Maree Keenan: None declared, Laura C Coates: None declared
Дисертації з теми "Coates and Company"
1
Cave, Christopher. "On coarse geometric properties of discrete and locally compact groups." Thesis, University of Southampton, 2015. https://eprints.soton.ac.uk/384182/.
Повний текст джерела
2
Dai, Ruxin. "Richardson Extrapolation-Based High Accuracy High Efficiency Computation for Partial Differential Equations." UKnowledge, 2014. http://uknowledge.uky.edu/cs_etds/20.
Повний текст джерелаАнотація:
In this dissertation, Richardson extrapolation and other computational techniques are used to develop a series of high accuracy high efficiency solution techniques for solving partial differential equations (PDEs).
A Richardson extrapolation-based sixth-order method with multiple coarse grid (MCG) updating strategy is developed for 2D and 3D steady-state equations on uniform grids. Richardson extrapolation is applied to explicitly obtain a sixth-order solution on the coarse grid from two fourth-order solutions with different related scale grids. The MCG updating strategy directly computes a sixth-order solution on the fine grid by using various combinations of multiple coarse grids. A multiscale multigrid (MSMG) method is used to solve the linear systems resulting from fourth-order compact (FOC) discretizations. Numerical investigations show that the proposed methods compute high accuracy solutions and have better computational efficiency and scalability than the existing Richardson extrapolation-based sixth order method with iterative operator based interpolation.
Completed Richardson extrapolation is explored to compute sixth-order solutions on the entire fine grid. The correction between the fourth-order solution and the extrapolated sixth-order solution rather than the extrapolated sixth-order solution is involved in the interpolation process to compute sixth-order solutions for all fine grid points. The completed Richardson extrapolation does not involve significant computational cost, thus it can reach high accuracy and high efficiency goals at the same time.
There are three different techniques worked with Richardson extrapolation for computing fine grid sixth-order solutions, which are the iterative operator based interpolation, the MCG updating strategy and the completed Richardson extrapolation. In order to compare the accuracy of these Richardson extrapolation-based sixth-order methods, truncation error analysis is conducted on solving a 2D Poisson equation. Numerical comparisons are also carried out to verify the theoretical analysis.
Richardson extrapolation-based high accuracy high efficiency computation is extended to solve unsteady-state equations. A higher-order alternating direction implicit (ADI) method with completed Richardson extrapolation is developed for solving unsteady 2D convection-diffusion equations. The completed Richardson extrapolation is used to improve the accuracy of the solution obtained from a high-order ADI method in spatial and temporal domains simultaneously. Stability analysis is given to show the effects of Richardson extrapolation on stable numerical solutions from the underlying ADI method.
3
Chun, Luh-Shun, and 陸順俊. "A study of production strategy evolution of plated coated steel of the company Y." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/95193025821208868680.
Повний текст джерелаАнотація:
碩士義守大學
管理學院管理碩士在職專班
99
At the present, industry’s manufacturing is facing the complex situations as product cycles getting shorter, market forecast being indefinite, and diversification of various customers’ demands. So the manufacturing strategies adopted by different enterprises, will be influenced by the internal, external environments and continuous evolution. When enterprises facing the external environment changes, how to use limited resources and manufacturing strategy to adjust the project, construct a new business model, rebuild the competitive advantage in the fierce market competition, would be the key to achieve its development and survival. This study uses qualitative empirical study of field research methods, and takes Y Company, a producer of coated steel products, as an example. Research the evolution from the embryonic stage till setting up factories overseas. Analyze the various stages of market options and market entering models. Using the B-B process model, establish the individual company manufacturing strategy and the evolutional production plan model. The individual company''s managing team, through the management activities, establishes manufacturing strategy and production planning. Logistically controls operation process model in different periods. Then achieves the individual company’s expanding in the business manufacturing territory and production planning, and causes the key strategy’s core competitiveness. This research is aiming at Y Company’s manufacturing strategy model, to issue seven propositions related to the organization’s operating, and establish the dynamic model of the evolution of the various stages, production strategy and production plan and logistic control of the executive functions. The results of this study can be used as the references of steel industry manufacturing strategy and production planning. And can also provide relevant industries as the references of the future’s extension and inference, enhance the manufacturing strategy and production plan performance, move towards the development of effective business model. Then cause a sustainable competitive advantage, improve the international competitiveness of Taiwan steel industry’s capability.
4
Chuang, Kuo-Hsin, and 莊國鑫. "A Study of the Dumping Predictive Information Systems on Coated Steel Products – A Case Study of S Company." Thesis, 2005. http://ndltd.ncl.edu.tw/handle/22932881719012634386.
Повний текст джерелаАнотація:
碩士國立中山大學
資訊管理學系研究所
93
After joining in the World Trade Organization (WTO), the Taiwan’s steel import tariff has been comprehensively reduced to almost nil customs duties (duty-free) since the year 2004. As a result of overwhelming importation of steel products and continuous investment in enhancing and enlarging output capabilities made by local steel manufacturers, the domestic steel markets are showing a tendency to a surplus status of supply over demand. However, due to the increasingly strong demand of steel materials made by the China mainland in the recent years, it has been not only greatly helped put off the execution of the world-wide scattered anti-dumping trade remedy assistance measures since the year 2000, but also benefited the domestic major steel manufacturers adjusting and improving their market structure and profit advantages in time. This enables the local steel producers to gradually enlarge their export quantity and aggressively expand their steel output on China mainland in the meantime. While the steel industries are boomingly developing, the international steel prices are rising and the steel market bargains are boosting, I am firmly confident that only the steel enterprises are able to concentrate their attention on what the anti-dumping measures formulated by WTO are stated, and to take appropriate dealing actions in the meantime, the competitive edge will be able to be elevated by the domestic steel producers. Therefore, to immediately setup information system on the forecast of dumping prediction and the knowledge of anti-dumping measures is a prerequisite to facilitate enhancing the enterprise’s competitive edge and superiority. The results of this research are made into two fields on the application of a dumping prediction about the coated/galvanized plate steel products. i.e. (1) In line with the WTO regulations and the US anti-dumping law, I have made various collection concerning the information of law articles, dumping items, documents as well as miscellaneous information and have combined them into one consolidated concept to construct an up-dated dumping pre-warning alarm system. (2) Further study was made on the pre-warning subject concerning price negotiations and price finalizations of the S company’s marketing department between the phases of order reception and goods issue. The result I discovered is that it is critically important for the enterprise to systematically pin down and appropriately structure its sales prices in advance and timely notice the pre-warning alarm measures in linking with the marketing model team before the entrepreneur is facing an international anti-dumping complaint or accusation in this regard.
5
陳正剛. "The Research of the Competitive Strategies for Industrial Product-- An Example of The Coated Fine Paper in Company A." Thesis, 2005. http://ndltd.ncl.edu.tw/handle/40148417917048220540.
Повний текст джерелаАнотація:
碩士國立臺灣科技大學
工業管理系
92
In 2004, the zero tariff policy for paper importation into Taiwan was implemented. Thus, loads of coated papers from North America, Europe, Japan and Mainland China were increasingly being imported into Taiwanese market. These countries have the advantages of abundant natural forest resources and large economic scale. Abrupt rise of Mainland economy, factory investments from foreigners, and constant introduction of new products into the market caused an imbalance between supplies and demands. Due to Taiwan’s geographical and cultural characteristics, the extent of negative effects was relatively tremendous. Thus, the Taiwanese market share in the paper industry is critically challenged. The case study of this research is a leading Taiwanese privately-owned paper production company in the country. It has the most market share in the domestic paper production market. Furthermore, it was the company that first incorporated nano-technology into the making of coated papers, a process of applying coating on regular papers. The case company can be considered as the representative of paper industry in Taiwan as it has the highest revenue in the domestic paper industry and is the biggest coated paper manufacturer in the country. This research bases the case company as its research subject, and utilizes the structure of Porter’s Five Forces to analyze the competitive status of our domestic paper industry. This research will also look into possible strategies the case company could employ to overcome disadvantages in the industrial competition.
Книги з теми "Coates and Company"
1
Hire, Coates, ed. Coates, the first one hundred years. Miranda, N.S.W: Coates Hire, 1985.
Знайти повний текст джерела
2
Coates, Kevin. Kevin Coates: Goldsmith : a Goldsmiths' Company exhibition, 26th June-19th July 1991. [London]: Goldsmiths' Company, 1991.
Знайти повний текст джерела
3
National Institute for Occupational Safety and Health., ed. American Fuel Cell and Coated Fabrics Company, Magnolia, Arkansas. [Atlanta, Ga.?]: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1993.
Знайти повний текст джерела
4
National Institute for Occupational Safety and Health, ed. American Fuel Cell and Coated Fabrics Company, Magnolia, Arkansas. [Atlanta, Ga.?]: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1993.
Знайти повний текст джерела
5
National Institute for Occupational Safety and Health., ed. American Fuel Cell and Coated Fabrics Company, Magnolia, Arkansas. [Atlanta, Ga.?]: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1993.
Знайти повний текст джерела
6
Davies, Robert. The conservation of a gelatin coated print and a 'company painting'. (London: Camberwell College of Arts), 1990.
Знайти повний текст джерела
7
R, Toothman Fred. Working for the Chessie System: Olde king coal's prime carrier. Huntington, W. Va: Vandalia Book Co., 1993.
Знайти повний текст джерела
8
Chu, Hsi-Yun. Market expansion strategy in the UK of a Taiwanese giftware company Coaster Associates Inc.. Oxford: Oxford Brookes University, 1997.
Знайти повний текст джерела
9
Society, Champlain, ed. "Opposition on the Coast": The Hudson's Bay Company, American coasters, the Russian-American Company, and Native traders on the Northwest Coast, 1825-1846. Toronto: The Champlain Society, 2019.
Знайти повний текст джерела
10
Jacquot, Claude. Max Alhau, Janine Boissard, Nadine Brun-Cosme, Georges-Olivier Châteaureynaud, Xavier Company, Florence Delaporte, Catherine Derbin, Shirley Dollé, Laure Fardoulis, Didier Goupil, Charles Le Quintrec, Anita Valléjo, Michel Host, Chantal Portillo, Didier Daeninckx, Monique Debruxelles, Hubert Haddad, Jacques Mazeau, Claude Pujade-Renaud, Laurine Rousselet, Frédérick Tristan, Cécile Wajsbrot et le bord de mer. Lévignacq: C. Jacquot, 2003.
Знайти повний текст джерелаЧастини книг з теми "Coates and Company"
1
Enberg, Tomi, Sari Alander, and Maria Paasivaara. "Onboarding for an Agile Software Development Company." In Lecture Notes in Business Information Processing, 144–62. Cham: Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-61154-4_10.
Повний текст джерелаАнотація:
AbstractThe global shortage of highly skilled employees has created a need for a more efficient onboarding process in software development companies. The experienced onboarding efficiency affects the new employee’s willingness to stay within the company and the efficiency of their work. Our case company transferred to a team-based organization structure, where agile teams were given high autonomy. Supervisor responsibilities were divided among different roles, such as people coaches and a lead team. We studied the onboarding process through a survey that was answered by 39 persons, as well as 18 interviews to gather details from the onboarding process. To validate the findings, workshops, and presentations were organized in the case company. We found that mentoring was experienced as the most important form of onboarding in the case company. The biggest challenges were lack of transparency, insufficient material availability, and lack of documentation. As solutions were suggested: a shared repository of onboarding materials, checklists for teams and mentors for onboarding new employees efficiently, and collecting team-specific materials to a single location.
2
Budnick, Greg. "Case Study: Process Rheology of Cover Coats at Engineered Storage Products Company." In Advances in Porcelain Enamel Technology, 133–34. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470640906.ch25.
Повний текст джерела
3
De Marchi, Damiano, Mirko Lalli, and Alessandro Mancini. "Monitoring online perception of environmental issues on coasts of Sicily." In Proceedings e report, 214–18. Florence: Firenze University Press, 2020. http://dx.doi.org/10.36253/978-88-5518-147-1.21.
Повний текст джерелаАнотація:
The analysis of big data on human experience (reviews, comments, ratings, etc.) can provide valuable insights to companies and institutions. This pioneer study applied the artificial intelligence proprietary tools of The Data Appeal Company for a different aim: monitoring the online perception of environmental issues on 88 beaches of Sicily. Results proved that it is possible to monitor environmental situation even to sites where there are no other kind of monitoring, using as bases the free and available contents posted by humans online, processed and analyzed by artificial intelligence
4
Sonoda, Tsutomu, Kenji Katou, Insu Jeon, Yasuo Yamada, and Tadashi Asahina. "Fabrication of Sintered Compact from Aluminum Powder Coated with Tin Deposits by Magnetron DC Sputtering." In Materials Science Forum, 353–57. Stafa: Trans Tech Publications Ltd., 2006. http://dx.doi.org/10.4028/0-87849-423-5.353.
Повний текст джерела
5
Ohrnberger, Tobias, C. Becker, and H. Härle. "Exhaust gas treatment with compact DEF mixing section and SCR coated DPF for future emission standards." In Proceedings, 893–909. Wiesbaden: Springer Fachmedien Wiesbaden, 2014. http://dx.doi.org/10.1007/978-3-658-05130-3_64.
Повний текст джерела
6
Kraus, Jakob, Simon Brehm, Cameliu Himcinschi, and Jens Kortus. "Structural and Thermodynamic Properties of Filter Materials: A Raman and DFT Investigation." In Multifunctional Ceramic Filter Systems for Metal Melt Filtration, 111–34. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-40930-1_5.
Повний текст джерелаАнотація:
AbstractThe contribution focuses on the accurate prediction of heat capacities for intermetallics, the estimation of reaction paths for coated and uncoated alumina foam filters in contact with metallic melts, and the investigation of thermally induced changes in various filters and filtercomponents. Density functional theory (DFT) was able to provide isobaric heat capacities for Al–Fe and Al–Fe-Si systems that outclassed the empirical Neumann–Kopp rule and matched the experimental values over a wide temperature range. Moreover, DFT calculations clarified that the formation of hercynite at the interface between alumina filters and steel melt was the result of a solid-state reaction involving high concentrations of FeO. Ex-situ Raman spectroscopy was used to compare carbon-bonded alumina filters using different bindersfrom Carbores®P to environmentally friendly lactose/tannin, as a function of heat treatment. For these carbon-bonded filters, the prominent D and G bands were used to confirm the existence of graphitization processes and determine the size of graphite clusters resulting from these processes. In order to investigate the pyrolysis processes occurring in selected binder constituents of the lactose/tannin filters, the evolution of Raman spectra with temperature was analyzed via in-situ measurements. Wherever it was appropriate, experimental Raman data were compared with DFT-simulated spectra. Further, Raman spectroscopy was used to study the thermally induced formation of metastable alumina, helping to understand the structural changes that take place during the transformation of boehmite (γ-AlO(OH)) to corundum (α-Al2O3) via metastable transition phases: γ-Al2O3, δ-Al2O3, and θ-Al2O3.
7
Ceron, Tanise, Ana Barić, André Blessing, Sebastian Haunss, Jonas Kuhn, Gabriella Lapesa, Sebastian Padó, Sean Papay, and Patricia F. Zauchner. "Automatic Analysis of Political Debates and Manifestos: Successes and Challenges." In Robust Argumentation Machines, 71–88. Cham: Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-63536-6_5.
Повний текст джерелаАнотація:
AbstractThe opinions of political actors (e.g., politicians, parties, organizations) expressed through claims are the core elements of political debates and decision-making. Political actors communicate through different channels: parties publish manifestos for major elections, while individual actors make statements on a day-to-day basis as reflected in the media. These two channels offer different approaches for analysis: Manifestos, on the one hand, are useful to characterize the parties’ positions at a global ideological level over time. In contrast, individual statements can be collected to analyze debates in particular policy domains on a fine-grained level, in terms of individual actors and claims. In this article, we summarize a series of studies we have carried out. We apply NLP-driven (semi-)automatic analyses on these two channels and compare their potentials and challenges. The fine-grained analysis yields rich insights into the communication but comes at the cost of three challenges: (a) a substantial hunger for manual annotation, introducing practical hurdles for analysis both within and across languages; (b) difficulties in claim classification arising from the uneven frequency distribution over the theory-based annotation schemas; (c) the need to map actor mentions onto canonical versions. Manifesto-based analysis avoids these challenges to a substantial extent when a more coarse-grained analysis of party positions is sufficient. We highlight the benefits and challenges of both approaches, and conclude by outlining perspectives for addressing the challenges in future research.
8
Wetzig, Tony, Matthias Schwarz, Leandro Schöttler, Patrick Gehre, and Christos G. Aneziris. "Functionalized Feeders, Hollowware, Spider Bricks and Starter Casting Tubes for Increasing the Purity in Steel Casting Processes." In Multifunctional Ceramic Filter Systems for Metal Melt Filtration, 815–31. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-40930-1_32.
Повний текст джерелаАнотація:
AbstractAlthough continuous casting became the state of the art for the casting of ordinary steel grades, ingot casting by bottom teeming still has relevance in the steelmaking industry, especially for the manufacturing of specialty and alloy steels. As for every casting process, the ever-increasing quality requirements by customers lead to increased demand for new technologies to increase the purity of the cast steel melt regarding its inclusion content. Due to the special design of the bottom-teeming ingot casting facility and the discontinuous operation as batch process, the application of filters is a promising approach. Tailored foam geometries were prepared based on additive manufacturing via selective laser sintering (SLS) and transformed into filters via modified replication techniques and flame spraying. Additionally to filter application, the functionalization and quality improvement of applied hollowware refractories has high potential to remove existing inclusions from the steel melt and avoid the formation of new inclusions during casting. The investigated hollowware components were manufactured by pressure slip casting on the basis of coarse-grained alumina compositions and subsequent functionalization by spray coating based on carbon-bonded alumina slurries. Simultaneous application of functionalized, “reactive” refractory components and flame-sprayed, “active” filters enables a combined filtration system which unites the advantages of the distinct filtration mechanisms. In the continuous casting of specialty steels, the conditions are more severe resulting in additional challenges regarding the application of filters. An approach investigated in this subproject is the use of extruded filter starter casting tubes above the tundish outlet. To achieve this, extrusion mixes based on cellulose derivatives and materials of the system Al2O3-ZrO2-C (AZC) were investigated for their suitability. The new concepts were tested in industrial casting trials in cooperation with the company Deutsche Edelstahlwerke Specialty Steels Europe GmbH (DEW). Post-mortem, the former melt-refractory interface of the applied components was investigated and steel samples from the ladle, the gating system and the ingot were analyzed in comparison to untreated samples.
9
Coates, Jamie, and Jennifer Coates. "Re-Presenting Sino-Japanese Relations through Flavors of Youth." In Transnational East Asian Studies, 169–84. Liverpool University Press, 2023. http://dx.doi.org/10.3828/liverpool/9781802077292.003.0011.
Повний текст джерелаАнотація:
Jamie Coates and Jennifer Coates initially note how the relationship between China and Japan is often represented as typified by conflict, tension, and difference. They then identify how the Sino-Japanese context is also a trans- national field of creative collaboration, co-production, and shared reception of texts that often emphasise popular cultural continuities shared between the two countries. Taking Flavors of Youth (詩季織々, J. Shiki ori ori, 肆式 青春, C. Si shi qing chun, by Li Haoling, Jiaoshou Yi Xiaoxing, and Takeuchi Yoshitaka, 2018) as a key text that exemplifies recent developments in Sino-Japanese creative collaboration, they identify an emphasis on shared emotional states and affective commonalities between everyday China and Japan. Flavors of Youth was developed by Japanese production studio CoMix Wave Films and the Chinese animation company Haoliners Animation League as a co-production for Netflix and StudioCanal. At the industry level, it draws attention to the transnational production of animation styles that were once imagined as distinctly Japanese, and represents the rise of collaborations within the Northeast Asian media industry.
10
"THE COMPANY OF OUR GREAT MINDS." In The Coasts of Bohemia, 18–28. Princeton University Press, 2020. http://dx.doi.org/10.2307/j.ctv10vm14j.7.
Повний текст джерелаТези доповідей конференцій з теми "Coates and Company"
1
Asano, Hitoshi, D. Schafer, E. Bouyer, and Hans Muller-Steinhagen. "DEVELOPMENT OF PLASMA SPRAY-COATED TUBES FOR COMPACT EVAPORATOR." In Compact Heat Exchangers and Enhancement Technology for the Process Industries - 2003. Connecticut: Begellhouse, 2023. http://dx.doi.org/10.1615/978-1-56700-195-2.540.
Повний текст джерела
2
Pankratz, Josh. "Understanding Arc Energy: Methods to Measure, Compare and Control Arc Energy." In 64th Society of Vacuum Coaters Annual Technical Conference. Society of Vacuum Coaters, 2021. http://dx.doi.org/10.14332/svc21.proc.0028.
Повний текст джерела
3
Kim, H. J., and Y. J. Kim. "Microstructural Evaluations of the Plasma Transferred Arc Coated Layers on the Hardness, Wear Resistance, and Corrosion for the Hardfacing of Ni- and Co-Based Alloys." In ITSC 1998, edited by Christian Coddet. ASM International, 1998. http://dx.doi.org/10.31399/asm.cp.itsc1998p0217.
Повний текст джерелаАнотація:
Abstract Commercially available coating techniques such as "open arc" and "spray & fuse" methods were used to compare the microstructural development with the plasma transferred arc (PTA) coating process for the hardfacing of NiCrBSi and Stellite 6 alloys. Denser eutectic structure was observed in the case of PTA coated layers of the Stellite 6 alloys than those of open arc weld-surfacing process. The shape of both carbides and borides in the 16C alloy coated by PTA processing were also obtained to have coarse morphology of carbides and borides while the "spray & fused" layers show a needle shape with finer distributions. Possible thermal history during each coating process is discussed. Based on microstructural observation, the hardness, wear resistance, and corrosion behaviors are reported. As expected, the alloy properties are directly related to their constituents of microstructure.
4
Kozlovsky, W. J., W. P. Risk, W. Lenth, G. L. Bona, H. Jaeckel, and D. J. Webb. "Resonator-enhanced frequency doubling in an extended-cavity diode laser." In Compact Blue-Green Lasers. Washington, D.C.: Optica Publishing Group, 1993. http://dx.doi.org/10.1364/cbgl.1993.pp173.
Повний текст джерелаАнотація:
Compact, efficient, diode-laser-based blue light sources are useful for many applications including optical storage and laser printing. Blue light can be generated by frequency doubling the output of reliable, high-power 860-nm lasers in potassium niobate. The Second Harmonic Generation (SHG) conversion efficiency can be substantially increased by placing the nonlinear crystal inside of a resonator in order to increase the infrared intensity in the crystal.1,2,3,4 The build-up of a high infrared intensity and efficient generation of blue output requires precise frequency matching of the diode laser and the SHG resonator. Previously, electronic locking1 and weak optical feedback techniques2,3,4 have been used to maintain this frequency matching. Electronic locking has the disadvantage of requiring an optical isolator to prevent destabilization of the laser frequency by light scattered from the resonator. Weak optical feedback has the disadvantage of requiring electronic control of the phase of the optical feedback as well as precise control of the feedback amplitude.3,4 We describe the operation of an antireflection-coated GaAlAs diode laser in an extended laser cavity that contains the SHG resonator as an intracavity element. The use of an antireflection coating on the laser and strong optical feedback is intended to suppress coupled-cavity effects and produce stable operation of the laser at a single frequency that is resonant with the SHG resonator. With the extended cavity we have obtained blue output powers of up to 12.5 milliwatts.
5
Lee, Jang-Ho, Kyeongo Cho, Tae-Joo Kim, Hyeong-Dae Kim, and Moo Hwan Kim. "HEAT AND MASS TRANSFER ON TEFLON COATED TUBES USED FOR LATENT HEAT RECOVERY." In Compact Heat Exchangers and Enhancement Technology for the Process Industries - 2003. Connecticut: Begellhouse, 2023. http://dx.doi.org/10.1615/978-1-56700-195-2.370.
Повний текст джерела
6
Edwards, Chris, and Lynford L. Goddard. "Modeling of compact Pd coated VCSELs for hydrogen sensing." In SPIE OPTO, edited by James K. Guenter and Chun Lei. SPIE, 2011. http://dx.doi.org/10.1117/12.874235.
Повний текст джерела
7
Tawancy, H. M., and Luai M. Al-Hadhrami. "Role of Platinum in Thermal Barrier Coatings Used in Gas Turbine Blade Applications." In ASME Turbo Expo 2009: Power for Land, Sea, and Air. ASMEDC, 2009. http://dx.doi.org/10.1115/gt2009-59153.
Повний текст джерелаАнотація:
Current technology of thermal barrier coating systems used in gas turbine blade applications relies upon the use of a metallic bond coat, which has a two-fold function: i) it develops a thin layer of aluminum oxide enhancing the adhesion of the ceramic top coat, and ii) it provides an additional resistance to oxidation. It was the objective of this study to develop an understanding of the role of platinum in bond coats of the diffusion-type deposited on a nickel-base superalloy. Two Pt-containing bond coats were included in the study: i) a platinum-aluminide and ii) a bond coat formed by interdiffusion between an electroplated layer of platinum and the superalloy substrate. In both cases, the top ceramic coat was yttria-stabilized zirconia. For reference purposes, a simple aluminide bond coat free of Pt was also included in the study. Thermal exposure tests at 1150 °C with a 24-hour cycling period to room temperature were used to compare the coating performance. Microstructural features were characterized by various electron-optical techniques. Experimental results indicated that Pt acts as a “cleanser” of the oxide-bond coat interface by decelerating the kinetics of interdiffusion between the bond coat and superalloy substrate. This was found to promote selective oxidation of Al resulting in a purer Al2O3 scale of a slower growth rate increasing its effectiveness as “glue” holding the ceramic top coat to the underlying metallic substrate. However, the exact effect of Pt was found to be a function of the state of its presence within the outermost coating layer. Of the two bond coats studied, a surface layer of Pt-rich gamma prime phase (L12 superlattice) was found to provide longer coating life in comparison with a mixture of PtAl2 and beta phase. This could be related to the effectiveness of gamma prime phase as a sink for titanium minimizing its detrimental effect on the adherence of aluminum oxide.
8
King, Jeffrey C. "A high power, Coated Particle Fuel Compact Radioisotope Heat Unit." In Space technology and applications international forum - 2001. AIP, 2001. http://dx.doi.org/10.1063/1.1358007.
Повний текст джерела
9
Richer, P., M. Yandouzi, M. Brochu, A. Zu´n˜iga, A. Corbeil, and B. Jodoin. "Oxidation Behaviour of Conventional and Nanocrystalline CoNiCrAlY Bond Coats Manufactured by Cold Spray." In ASME 2011 Turbo Expo: Turbine Technical Conference and Exposition. ASMEDC, 2011. http://dx.doi.org/10.1115/gt2011-45747.
Повний текст джерелаАнотація:
The purpose of the present study is to investigate and compare the oxidation behaviour of conventional and nanocrystalline CoNiCrAlY bond coats. The nanocrystalline feedstock powder is produced from the conventional feedstock powder using the cryogenic milling process. Conventional and nanocrystalline bond coats are produced using the Cold Spray (CS) process in order to avoid the onset of thermally induced grain growth and minimize the inclusion of oxides in the bond coat microstructure. The oxidation behaviour of free-standing CoNiCrAlY coating samples is determined by means of isothermal oxidation experiments consisting of heat treatments in air at 1000°C for various periods of time. Characterization of the feedstock powders and resulting CS coatings, as well as investigation of the oxide scale growth dynamics, is achieved by means of SEM, XRD and TEM analyses. Mass gain measurements were also carried out throughout the oxidation tests to evaluate oxide growth rates.
10
Pisani, M., M. Zucco, A. Egidi, and S. Mottini. "New applications for Compact Optical Attitude Sensor (COATS) for space." In 2019 IEEE 5th International Workshop on Metrology for AeroSpace (MetroAeroSpace). IEEE, 2019. http://dx.doi.org/10.1109/metroaerospace.2019.8869688.
Повний текст джерелаЗвіти організацій з теми "Coates and Company"
1
Ando, Junji, Toshiyuki Saito, Naoyuki Sakai, Toshifumi Sakai, Hajime Fukami, Kazuyuki Nakanishi, Hiroyuki Mori, Hideo Tachikawa, and Toshihide Ohmori. Development of Compact, High Capacity 4WD Coupling With DLC-Si-Coated Electromagnetic Clutch. Warrendale, PA: SAE International, May 2005. http://dx.doi.org/10.4271/2005-08-0033.
Повний текст джерела
2
Price, J. T., and J. F. Gransden. Carbonization of conventional and partially briquetted charges of a Canadian steel company blend containing western Canadian coals. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 1985. http://dx.doi.org/10.4095/302613.
Повний текст джерела
3
Van Rooyen, Isabella Johanna, Paul Andrew Demkowicz, Jessica Lori Riesterer, Brandon Douglas Miller, Dawn Elizabeth Janney, Jason Michael Harp, and Scott Arden Ploger. Electron Microscopic Examination of Irradiated TRISO Coated Particles of Compact 6-3-2 of AGR-1 Experiment. Office of Scientific and Technical Information (OSTI), December 2012. http://dx.doi.org/10.2172/1364097.
Повний текст джерела
4
Masashi Shimada. Report on the deuterium retention in CVD coated W on SiC in support of the Ultramet Company?s Small Business Innovation Research (SBIR) project: SOW DE-FG02-07ER84941. Office of Scientific and Technical Information (OSTI), June 2012. http://dx.doi.org/10.2172/1054718.
Повний текст джерела
5
Ruschau. L51961 Coating Compatibility at Thermite Welds and Keyhole Excavations. Chantilly, Virginia: Pipeline Research Council International, Inc. (PRCI), December 2002. http://dx.doi.org/10.55274/r0010247.
Повний текст джерелаАнотація:
Patching and repairing high performance pipeline coatings requires a high performance repair material to ensure the integrity of the coating system. The application conditions are not optimized as they are during plant applications, so it is imperative that repair coatings applied to mainline coatings will adhere to all coated surfaces so that resources can be focused on optimizing application methods. Compatibility of repair coatings applied to thermite weld components may be inadequate for optimum field performance. When combined with the limiting factors of keyhole excavations it is important to use coatings which are not only compatible with the thermite welds but also are suitable for the keyhole application procedure. A series of 14 pipeline repair coatings were evaluated for their compatibility with the components of a thermite weld. Chemical compatibility was determined in terms of adhesion with the thermite weld individual components: polyethylene wire insulation, polyvinylchloride wire insulation, copper wire, steel, and copper/aluminum thermite alloy. The same coatings were evaluated for their suitability for application by keyhole excavation procedures. A keyhole excavation was simulated using a scaffold over filled soil boxes (dry soil) containing buried pipe sections, and each of the repair coatings was applied by a commercial keyhole excavation company. The ease of application and general suitability was rated. After backfilling and aging for six months, the samples were removed from the soil boxes and the coatings evaluated.
6
Wachen, John, Steven McGee, Don Yanek, and Valerie Curry. Coaching Teachers of Exploring Computer Science: A Report on Four Years of Implementation. The Learning Partnership, January 2021. http://dx.doi.org/10.51420/report.2021.1.
Повний текст джерелаАнотація:
In this technical report, we examine the implementation of a coaching model for teachers of the Exploring Computer Science course in Chicago Public Schools over a period of four academic years (from 2016-2017 to 2019-2020). We first provide a description of the coaching model and how it evolved over time. Next, we present findings from a descriptive analysis of data collected through logs of coaching interactions and surveys of ECS teacher coaches during the 2019-2020 school year. Coaching logs and survey data were also collected during the 2018-2019 school year and, where appropriate, we compare results across years. We then discuss the products that were produced by the coaching team to support the implementation of the model. Finally, we provide an overview of next steps for the coaching team in the 2020-2021 school year and beyond.
7
Letcher, Theodore, Julie Parno, Zoe Courville, Lauren Farnsworth, and Jason Olivier. A generalized photon-tracking approach to simulate spectral snow albedo and transmittance using X-ray microtomography and geometric optics. Engineer Research and Development Center (U.S.), June 2023. http://dx.doi.org/10.21079/11681/47122.
Повний текст джерелаАнотація:
A majority of snow radiative transfer models (RTMs) treat snow as a collection of idealized grains rather than an organized ice–air matrix. Here we present a generalized multi-layer photon-tracking RTM that simulates light reflectance and transmittance of snow based on X-ray micro- tomography images, treating snow as a coherent 3D structure rather than a collection of grains. The model uses a blended approach to expand ray-tracing techniques applied to sub-1 cm3 snow samples to snowpacks of arbitrary depths. While this framework has many potential applications, this study’s effort is focused on simulating reflectance and transmittance in the visible and near infrared (NIR) through thin snow- packs as this is relevant for surface energy balance and remote sensing applications. We demonstrate that this framework fits well within the context of previous work and capably reproduces many known optical properties of a snow surface, including the dependence of spectral reflectance on the snow specific surface area and incident zenith angle as well as the surface bidirectional reflectance distribution function (BRDF). To evaluate the model, we compare it against reflectance data collected with a spectroradiometer at a field site in east-central Vermont. In this experiment, painted panels were inserted at various depths beneath the snow to emulate thin snow. The model compares remarkably well against the reflectance measured with a spectroradiometer, with an average RMSE of 0.03 in the 400–1600 nm range. Sensitivity simulations using this model indicate that snow transmittance is greatest in the visible wavelengths, limiting light penetration to the top 6 cm of the snowpack for fine-grain snow but increasing to 12 cm for coarse-grain snow. These results suggest that the 5% transmission depth in snow can vary by over 6 cm according to the snow type.
8
Brushett, D. M., C. E. Beckett-Brown, M. B. McClenaghan, R. C. Paulen, J. M. Rice, A. Haji Egeh, and P. Pelchat. Till geochemical data for the Brazil Lake pegmatite area, southwest Nova Scotia, Canada (NTS 21-A/04, 20-O/16 and 20-P/13): samples collected in 2020, 2021, and 2022. Natural Resources Canada/CMSS/Information Management, 2024. http://dx.doi.org/10.4095/332384.
Повний текст джерелаАнотація:
This open file reports geochemical data for till samples collected as a part of a till geochemical and surficial mapping project around the Brazil Lake lithium-cesium-tantalum (LCT-type) pegmatite in southwestern Nova Scotia (NTS map sheets 21A/04, 20O/16 and 20P/13). The global rise in lithium demand has motivated the Geological Survey of Canada's (GSC) recent investigations of the Brazil Lake pegmatites to study surficial geochemistry methods that can be used to explore for lithium and associated critical minerals (i.e., Cs, Ta, Be, In, Sn, W). These types of deposits are important sources of lithium, tin, and rubidium and the primary source of tantalum. This research at Brazil Lake is being undertaken as part of the GSC's Targeted Geoscience Initiative Program and has been carried out in partnership with the Nova Scotia Department of Natural Resources and Renewables (NSDNRR). The goals of the research are to increase exploration success in regions covered by glacial sediments by documenting how critical minerals and associated elements are glacially dispersed in till from pegmatites at the Brazil Lake property. Newly available LiDAR data assisted in deciphering ice flow trajectories, which in turn, allowed for targeted till sampling. A total of 184 till samples were collected for till geochemistry in 2020, 2021 and 2022 and the data reported here include widely spaced regional samples collected across southwest Nova Scotia, proximal samples collected up-ice, overlying, and down-ice of the Brazil Lake pegmatites. The widely spaced till samples provide the regional context for the interpretation of the case study samples and assess the potential for additional pegmatites buried by extensive till cover. Data reported in this Open File include sample descriptions, location, site photos, and geochemical analyses of the coarse sand (1.0 - 2.0 mm) and silt + clay (&lt;0.063 mm) fractions. For the 2020 samples only, the &lt;0.002 mm (clay) fraction was also analyzed. Analyses over the 3 years (2020-2021-2022) include various combinations of different digestions or fusions to test and compare their efficacy for the various pathfinder elements for LCT pegmatites: aqua regia (partial) digestion, 2) Na peroxide fusion (total), 3) 4-acid (near total) digestion, 4) Li-meta/tetraborate fusion, 5) loss on ignition, and 6) portable X-ray fluorescence (XRF).
9
Health hazard evaluation report: HETA-90-246-2314, American Fuel Cell and Coated Fabrics Company, Magnolia, Arkansas. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, May 1993. http://dx.doi.org/10.26616/nioshheta902462314.
Повний текст джерела
10
Enhancing the use of coals by gas reburning-sorbent injection. Volume 3, Gas reburning-sorbent injection at Edwards Unit 1, Central Illinois Light Company. Office of Scientific and Technical Information (OSTI), October 1994. http://dx.doi.org/10.2172/53497.
Повний текст джерела